Solvay Ships Phase III Burn Agent To N.Y.; Aventis Sends DT Vaccine
Executive Summary
Solvay's investigational burn treatment Flammacerium (sulfadiazine/cerium) will be available to burn victims in New York under a compassionate use program approved by FDA Sept. 12.